BrianHKushnerMD

Pediatric Hematology & Oncology • New York, NY

Professor of Pediatrics, Cornell University-Weill Medical College

Overview of Dr. Kushner

Dr. Brian Kushner is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 41 years. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(872) 221-5812

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1983 - 1988
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1978 - 1980
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1976 - 1978
Johns Hopkins University School of MedicineClass of 1976

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 1976 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2003-2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008, 2011-2012
Join now to see all

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Start of enrollment: 1990 May 01
Completed
Phase 2
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Start of enrollment: 1992 Oct 01
Completed
Phase 2
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma Start of enrollment: 1994 Feb 01
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 2
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma Start of enrollment: 2005 Jun 01
Completed
Phase 1
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma Start of enrollment: 2005 Sep 09
Completed
Phase 1
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma Start of enrollment: 2009 May 27
Active, not recruiting
Phase 1, Phase 2
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation Start of enrollment: 2010 Aug 01
Completed
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma Start of enrollment: 2010 Aug 12
Completed
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma Start of enrollment: 2010 Aug 01
Terminated
Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow Start of enrollment: 2010 Aug 12
Completed
Phase 2
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Start of enrollment: 2012 Dec 01
Active, not recruiting
Phase 1, Phase 2
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma Start of enrollment: 2014 Mar 01
Completed
Not Applicable
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Start of enrollment: 2017 Jan 23
Active, not recruiting
Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma Start of enrollment: 2021 Aug 02
Recruiting
Phase 2
A Study of N9 Chemotherapy in Children With Neuroblastoma Start of enrollment: 2021 Jun 22
Recruiting
Early Phase 1
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma Start of enrollment: 2023 Sep 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

53 citations
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression
Irene Y. Cheung, Nai-Kong V. Cheung, Shakeel Modak, Audrey Mauguen, Yi Feng
Journal of Clinical Oncology. 2021-01-20
87 citations
Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Kim Kramer, Govind Ragupathi
Clinical Cancer Research. 2014-03-01
8 citations
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.
Irene Y Cheung, Audrey Mauguen, Shakeel Modak, Govind Ragupathi, Ellen M Basu
JAMA Oncology. 2023-02-01

Lectures

High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Y-mAbs Announces Naxitamab UpdateOctober 25th, 2019